Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28871349 | 1.00 | TP53 (0.51) | TP53CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL7274206 | 0.88 | ACE (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL8855103 | 0.88 | ACE (0.54) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL10425352 | 0.87 | FOLH1 (0.57) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL9924201 | 0.84 | MME (0.51) | TP53CYP1A2CYP2D6ALOX15TSHR | |
| SCHEMBL23925862 | 0.82 | MME (0.56) | CYP1A2MMEACECPA1ACE2 | |
| SCHEMBL1921156 | 0.82 | MME (0.56) | CYP1A2MMEACECPA1ACE2 | |
| SCHEMBL1921155 | 0.82 | MME (0.56) | CYP1A2MMEACECPA1ACE2 | |
| SCHEMBL6010262 | 0.82 | MME (0.49) | CYP1A2MMEL3MBTL1GGT1NPSR1 | |
| SCHEMBL6010258 | 0.82 | MME (0.49) | CYP1A2MMEL3MBTL1GGT1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | claimed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | claimed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| CN-101252926-A | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INNODIA INC (CA) | 2008-08-27 | — | — | CN | disclosed |
| CN-101193852-A | 4-Hydroxyisoleucine analogs and uses thereof | INNODIA INC (CA) | 2008-06-04 | — | — | CN | disclosed |
| EP-1874287-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | Innodia Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6482856-B1 | Method and composition for treating mammalian disease caused by inflammatory response | CELLULAR SCIENCES, INC. | 2002-11-19 | — | — | US | disclosed |
| US-5952384-A | CONTACTING THE MAMMALIAN CELL WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTS OF PYRUVATE AND PYRUVATE PRECURSOR CAPABLE OF REDUCING UNDESIRED INFLAMMATORY RESPONSE AND IS ANTIOXIDANT | CELLULAR SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5939459-A | CONTACTING WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTING OF PYRUVATE AND A PYRUVATE PRECURSOR AND IS PRESENT IN AN AMOUNT CAPABLE OF REDUCING THE UNDESIRED INFLAMMATORY RESPONSE AND IS AN ANTIOXIDANT | CELLULAR SCIENCES INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5798388-A | ANTIOXIDANT, ANTIASTHMA, ADMINISTERING PYRUVATE WITHOUT ALBUTEROL | CELLULAR SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | TP53 3898/4885CYP1A2 453/4885CYP2D6 372/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | TP53 2633/4885CYP1A2 347/4885CYP2D6 427/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | TP53 2171/4885CYP1A2 276/4885CYP2D6 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.